August 2013 Editor's Picks: Products from Eltherm and Netzsch - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

August 2013 Editor's Picks: Products from Eltherm and Netzsch

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Eltherm
Electronic temperature controllers are designed for demanding applications and high loads.

Eltherm’s electronic temperature controllers include the ELTC-14 with cable glands and the ELTC/H-14 with sockets to connect heated hoses or heating mats. Both models can be used to control the temperature of up to two heating cables with a temperature range from 0–390 °C. The robust controllers have splashproof housings with transparent covers. The signal contact can be operated either as a potential-free alarm, status, or release contact. The controller reliably switches up to 20 amp resistive load using a hybrid relay. An operating voltage of 90–260 volts AC allows the controllers to be used all over the world.

Netzsch
Disperser targets forces to separate agglomerated particles.

The Omega Economic Disperser from Netzsch disperses agglomerated particles in an energy-efficient manner by optimizing turbulence, cavitation, and shear forces. High efficiency leads to less heat development, reduced energy consumption, and lower cooling water consumption. The flow design leads to low wear (even with abrasive substances) and lower maintenance costs. The system can be adapted to different operating conditions or formulations using the adjustable nozzle. The Omega is available in four sizes ranging from 30 L/h to 4000 L/h. The Omega won the Innovation Award for the Plant Engineering and Processing Components category at the Powtech 2013 conference.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Equipment and Processing Report,
Click here